Latinas more likely to regret breast cancer treatment decisions

Nov 18, 2008

Latina women who prefer speaking Spanish are more likely than other ethnic groups to express regret or dissatisfaction with their breast cancer treatment, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

Despite receiving similar treatment, Latina women were 5.6 times more likely than white women to report high levels of dissatisfaction and regret about their breast cancer treatment decision.

The researchers found that Latinas and other ethnic groups had similar levels of involvement with their doctor in deciding the treatment plan. But Latinas were more likely to say they would have preferred to be more involved in the decision making.

Researchers surveyed 925 women with non-advanced breast cancer from the Los Angeles area. Women were asked about the decision making process in choosing their breast cancer treatment. Nearly half of the women surveyed were Latina, with a quarter preferring to speak Spanish. These women were 3.5 times more likely than English-speaking Latinas to have difficulty understanding written information about breast cancer.

"Even though they received similar amounts of information as whites, Latinas who prefer speaking Spanish reported a strong desire for more information. Doctors may need to make additional effort to ensure this information is understandable and culturally appropriate for all ethnic groups to improve the decision making process for breast cancer patients," says lead study author Sarah T. Hawley, Ph.D., assistant professor of internal medicine at the U-M Medical School and a research investigator at the VA Ann Arbor Healthcare System.

Source: University of Michigan

Explore further: Clumped cancer cells spread more efficiently through the body than lone ones

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

18 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

22 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.